DEVELOPMENT AND ASSESSMENT OF LIPOSOMAL NASAL SPRAY FOR THE TREATMENT EPILEPSY

Background: Levetiracetam is a pyrrolidine class antiepileptic drug mainly used to treat epilepsy and seizures. Objective: The purpose of this research was to synthesize a liposomal nasal spray incorporating levetiracetam for nose to brain delivery in epilepsy. Materials and methods: The preparation method employed thin film hydration to prepare liposomes loaded with levetiracetam with lecithin and tween 80 at different concentrations. The liposome formed were characterized in terms of particle size and entrapment efficiency. Finally, the prepared liposomes were converted into nasal spray and characterized for drug content, pH, viscosity, in vitro release profile, clarity, Ex-vivo permeation study. Results: The synthesized levetiracetam liposome had high entrapment efficiency of 75.6%, and 99.21%, with particle size ranging between 60-200 nm. The shape of the transferosomes was established using scanning electron microscopy; the results depicted spherical-shaped vesicles. Conclusion: Levetiracetam was efficiently integrated into Liposomal nasal formulation. Delivering drug molecules across nasal mucosa fosters a new longing. This is goals achievement for systemic transport of medications, thereby enhancing patient compliance. The F6 and NS6 demonstrated the highest drug release in an 8-hour by ex vivo drug release diffusion investigation.